Publication details
Co nás čeká v léčbě dyslipidemií?
| Authors | |
|---|---|
| Year of publication | 2014 |
| Type | Article in Proceedings |
| Conference | Vnitřní lékařství 2014 |
| MU Faculty or unit | |
| Citation | |
| Field | Biochemistry |
| Keywords | dyslipidemia; hypolipidemics |
| Description | In the treatment of dyslipidemia is currently no fundamental change and essential medicines continue to statins, which can be combined with fibrates or ezetimibe and in a relatively short term, is an inhibitor of PCSK 9. From a population perspective, to reduce cardiovascular disease crucial lifestyle changes. |